Company intelligence / Profile preview

CN

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

CN Bio's PhysioMimix® technology has achieved FDA recognition with the first co-publication between a drug regulator and a microphysiological systems provider. The platform has been adopted by 13 leading pharmaceutical companies and supported Inipharm's INI-822 for metabolic liver disease treatment, which is now in clinical testing.

Therapeutic areas: Other
Modalities: Device
Industry: Non-Drug Biotech

Partnerships

Pharmaron (strategic partnership for validation and co-development of organ-on-chip solutions)Primetech Corporation (distribution partnership in Japan)SCINCO (distribution partnership in South Korea)Altis Biosystems (partnership to develop next-generation Gut/Liver microphysiological system)Lonza (distribution agreement for pre-validated hepatocytes)LifeNet Health LifeSciences (distribution agreement for validated primary human cells)

Beyond the preview

Go deeper on CN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CN.

Explore the full profile